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SIV/HIV-1 (SHIV) chimeric clones, constructed by substituting portions of the pathogenic molecular clone SIVmac239 with
counterpart portions from HIV-1 clones, provide a means to analyze functions of selected HIV-1 genes in vivo in nonhuman
primates. Our studies focused on SHIVSF33, which contains the vpu, tat, rev, and env genes of the cytopathic, T-cell line tropic clone
HIV-1SF33 (subtype-B); this clone has a premature stop codon in the vpu gene. In three juvenile macaques inoculated intravenously
with SHIVSF33, low-level persistent infection was established; no disease was observed for a period of .2 years. However, at ;16
months p.i., one of four SHIVSF33-infected juvenile macaques exhibited an increase in virus load, depletion of CD41 T cells in
peripheral blood and lymph nodes, and other symptoms of simian AIDS (SAIDS). Virus recovered from this animal in the
symptomatic stage was designated SHIVSF33A (A, adapted); this virus displayed multiple amino acid sequence changes throughout
the HIV-1 env gene compared with the input SHIVSF33 clone. Additionally, a mutation in all clones from SHIVSF33A restored the open
reading frame for the vpu gene. In vitro evaluations in tissue-culture systems revealed that SHIVSF33A replicated to higher levels
and exhibited greater cytopathicity than SHIVSF33. Furthermore cloned env genes for SHIVSF33A were more fusogenic in a
cell-fusion assay compared with the env gene of the SHIVSF33. Intravenous inoculation of SHIVSF33A into juvenile and newborn
macaques resulted in a rapid decline in CD41 T cells to very low levels and development of a fatal AIDS-like disease. A cell-free
preparation of this pathogenic chimeric virus also established persistent infection when applied to oral mucosal membranes of
juvenile macaques and produced a fatal AIDS-like disease. These studies on pathogenic SHIVSF33A establish the basis for further
investigations on the role of the HIV-1 env gene in virus adaptation and in mechanism(s) of immunodeficiency in primates;
moreover, the chimeric virus SHIVSF33A can play a role in elucidating mucosal membrane transmission and development of
antiviral vaccines in newborns as well as juvenile and adult macaques. © 1999 Academic Pressc
i
d
a
m
m
s
1
l
w
t
s
t
v
w
h
t
t
v
a
d
w
sINTRODUCTION
Infection of macaques with selected strains of simian
mmunodeficiency virus (SIV) is a valuable model for
nvestigating many aspects of acquired immunodefi-
iency syndrome (AIDS) because of limitations of various
nimal models for human immunodeficiency virus type-1
HIV-1) infection and disease (reviewed in Gardner and
uciw 1997). To address issues focused on the functions
nd immunological properties of the HIV-1 env gene in
onhuman primate models, chimeric viruses have been
onstructed between molecular clones of SIVmac and
arious strains of HIV-1 (Shibata et al., 1991; reviewed in
verbaugh et al., 1997). These chimeras, designated
HIV (Li et al., 1992), contain an HIV-1 DNA fragment
ncoding tat, rev, vpu, and env cloned into the genome of
he proviral form of SIVmac239, which is a clone that
auses simian AIDS (SAIDS) in macaques (Kestler et al.,
990). Pathogenic SHIV strains that produce CD41 T-cell
epletion and an AIDS-like disease were produced by
ultiple serial passage of SHIV clones through ma-
1 To whom reprint requests should be addressed. Fax: (530) 752-
548. E-mail: paluciw@ucdavis.edu.042-6822/99 $30.00
opyright © 1999 by Academic Press
ll rights of reproduction in any form reserved.
112aques (Joag et al., 1996; Reimann et al., 1996). Accord-
ngly, SHIV clones containing HIV-1 env genes exhibiting
ifferent phenotypes (e.g., cell tropism, coreceptor us-
ge, cytopathicity) are being used to investigate env-
ediated mechanisms of immunodeficiency and trans-
ission through mucosal membranes and in vaccine
tudies (reviewed in Haga et al., 1998; Ruprecht et al.,
998; also see Kuiken 1997).
The present report describes the consequences of
ong-term infection of newborn and juvenile macaques
ith SHIVSF33, which contains the env gene of the T-cell
ropic, cytopathic isolate HIV-1SF33. In a previous in vivo
tudy, SHIVSF33 was shown to establish persistent infec-
ion in four juvenile macaques; after an initial peak of
iremia in the acute phase (2–4 weeks p.i.), virus levels
ere low and all four animals remained healthy with no
ematological or clinical abnormalities for an observa-
ion period of 1 year (Luciw et al., 1995). However, one of
hese four juvenile macaques exhibited an increase in
irus load at ;1.5 years after infection. This increase was
ccompanied by a dramatic decline in CD41 T cells and
evelopment of SAIDS. Virus recovered from this animal
as designated SHIVSF33A (A, adapted). In a previous
tudy, SHIVSF33A was shown to infect adult female rhesus
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113SHIV AND SIMIAN AIDS IN MACAQUESacaques by application of cell-free virus to vaginal
ucosal membranes (Harouse et al., 1998). In the
resent study, we examined the pathogenic properties of
HIVSF33A in both newborn and juvenile macaques and
ompared intravenous and oral mucosal membrane
outes of inoculation. Additionally, sequence changes in
he env gene of SHIVSF33A and in vitro replication prop-
rties of this virus also were analyzed. Understanding
he effects of such sequence changes in HIV-1 genes in
he chimeric virus will be important for defining molecu-
ar mechanisms that account for viral adaptation to AIDS
athogenesis in nonhuman primates.
RESULTS
solation of a pathogenic SHIV
In a previous study, we inoculated four juvenile rhesus
acaques (Mmu 25814, Mmu 26074, Mmu 26131, and
mu 26240) with SHIVSF33, a chimeric virus containing
he env gp160 gene as well as the vpu, tat, and rev genes
f the T-cell line tropic HIV-1SF33 clone (Fig. 1A) (Luciw et
l., 1995). For an observation period of 1 year, virus load
n peripheral blood and lymph nodes remained low in all
our animals; no hematological abnormalities or other
igns of disease were manifest (Luciw et al., 1995).
owever, one of these macaques (Mmu 25814), exhib-
ted an increase in virus load (Fig. 2A) with a concurrent
ecline in CD41 T cells in peripheral blood at 72 weeks
fter inoculation (Fig. 2B). For several weeks there-
fter, virus load in Mmu 25814 was as high as in
he two juvenile macaques (Mmu 26084 and Mmu
7098) infected with the pathogenic molecular clone
IVmac239nef1 (Fig. 2A). By 104 weeks, the number of
D41 T cells in Mmu 25814 declined to ,50/ml (Fig. 2B),
nd this animal developed chronic diarrhea and lost
20% of its body weight in the interval from 72 to 104
eeks. CD81 T-cell numbers in peripheral blood re-
ained within the reference range (.1000 cells/ml)
hroughout the course of infection, whereas the CD4/
D8 T-cell ratio in both peripheral blood and lymph node
iopsy samples dropped to ,0.1 from 72 weeks onward
data not shown). In the macaques infected with the
athogenic molecular clone SIVmac239nef1, levels of
D41 T cells also declined to low levels in the late stage
f infection (Fig. 2B).
Because of severe cachexia, Mmu 25814 was eutha-
ized at 128 weeks. Major pathological findings at nec-
opsy were disseminated lymphoid hyperplasia, lym-
hoid depletion in multiple lymph nodes, and interstitial
neumonia due to the opportunistic pathogen, Pneumo-
ystis carinii (Table 1). Cellular distribution of viral RNA
as determined in Mmu 25814 by a method combining in
itu hybridization for viral RNA and immunohistochemis-
ry for cell markers. In lymph node biopsies collected
rom Mmu 25814 at 92 weeks p.i., macrophages (HAM-
6-positive cells) were the main cells expressing viral
NA; a much smaller proportion of CD31 T cells con-ained detectable viral RNA (Figs. 3A and 3B). The same
attern of localization of virus, largely in macrophages,
as observed in a lymph node biopsy sample collected
rom Mmu 25814 at 118 weeks p.i. (data not shown). The
ther three juvenile macaques inoculated with SHIVSF33
ave remained healthy with normal hematological pa-
ameters and very low virus load for .2 years p.i. (data
ot shown).
nfection of juvenile macaques with pathogenic
HIVSF33A
To determine whether the chimeric virus changed and
cquired properties of a pathogenic virus during the
ourse of infection in Mmu 25814, several inoculation
tudies were performed in rhesus macaques. Figure 1B
llustrates the experimental plan, which included blood
ransfusion from Mmu 25814 to juvenile macaques and
nfection of juvenile and newborn macaques with cell-
ree virus isolated from Mmu 25814. Five milliliters of
lood collected from Mmu 25814 at 24 and at 104 weeks
as transfused into uninfected healthy juvenile ma-
aques. The two juvenile animals (Mmu 25392 and Mmu
6106; Fig. 1B), receiving a blood transfusion from Mmu
5814 at 24 weeks p.i., showed low virus load, CD41 T
ell levels .400 cells/ml, and no clinical signs through-
ut the 2-year period of observation (data not shown). In
triking contrast, the two animals (Mmu 27823 and Mmu
7843; Fig. 1B) receiving a blood transfusion from Mmu
5814 at 104 weeks p.i. contained moderate levels of
irus throughout infection (Fig. 4A) and exhibited a rapid
ecline in CD41 T cells in peripheral blood (Fig. 4B) and
dramatic reduction in CD4/CD8 ratios in lymph nodes
data not shown). Because CD81 T cells generally re-
ained within the reference range, the CD4/CD8 ratio
eclined to ,0.1 in the animals that showed the rapid
ecline in CD41 T cells (data not shown).
At necropsy at 35 weeks p.i., Mmu 27843 displayed
idespread lymphoid hyperplasia and severe pulmonary
nfection with the opportunist, Pneumocystis carinii (Ta-
le 1). Necropsy analysis of the second animal, Mmu
7823, at 51 weeks p.i. revealed widespread lymphoid
epletion and peritonitis with bacterial infections and
bscesses in the abdominal cavity (Table 1). Cellular
istribution of virus was examined by combined in situ
ybridization and immunohistochemistry analysis of
ymph node biopsies collected at 2, 8, 12, and 16 weeks
.i. from Mmu 27823 and Mmu 27843. Viral RNA was
etected predominantly in macrophages (these authors,
ata not shown). Additionally, at necropsy, the main cell
xpressing viral RNA was the macrophage in lung (Figs.
C and 3D), peripheral lymph nodes, gastrointestinal
ract and gut-associated lymphoid tissue, and bone mar-
ow (data not shown). Analysis of replication properties
n cultures of human monocyte-derived macrophages
evealed that SHIVSF33A replicated efficiently, whereas
HIVSF33 produced very low levels of virus (data not shown.)
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115SHIV AND SIMIAN AIDS IN MACAQUESCell-free virus, designated SHIVSF33A, was obtained
rom PBMC of Mmu 25814 at 104 weeks (Fig. 1B). To
nvestigate further the pathogenic potential of SHIVSF33A
nd to determine whether this virus could establish in-
ection via transmission through mucosal membranes,
he oral mucosal membranes of two juvenile macaques
ere exposed to a cell-free preparation of 26,000 TCID50
f SHIVSF33A (Mmu 27985 and Mmu 28498; Fig. 1B). Both
nimals showed moderate levels of virus in the acute
tage of infection; in the chronic stage, virus load was
ow for Mmu 28498 and very low for Mmu 27985 (Fig. 4A).
mu 28498 exhibited a rapid and sustained decline of
D41 T cells in peripheral blood at 2 weeks onward,
hereas CD41 T-cell levels remained .400 cells/ml in
mu 27985 throughout the course of infection (Fig. 4B).
lso, analysis of lymph node biopsies collected at 2
eeks and during the course of infection revealed a
ramatic reduction in the CD4/CD8 ratio in Mmu
8498 but not in Mmu 27985 (data not shown). At ;10
onths, Mmu 28498 developed chronic diarrhea and
ell’s palsy; this animal was euthanized at 50 weeks p.i.
alient findings at necropsy of Mmu 28498 included
idespread lymphoid depletion, thymic atropy, gastritis,
nd enteritis; multiple opportunistic pathogens were de-
ected in this animal (Table 1).
HIVSF33A infection and pathogenicity in newborn
acaques
To evaluate the pathogenic potential of SHIVSF33A in
ewborn macaques, a cell-free preparation of this virus
as inoculated into two newborn rhesus macaques by
he intravenous route (Mmu 29800 and Mmu 29801; Fig.
B). The infecting dose for each animal was 500 TCID50
f virus. Virus load was high in PBMC at 1 week after
nfection and thereafter declined to relatively low levels
n both animals (Fig. 5A). By 2 weeks, CD41 T-cell levels
ropped to ,50 cells/ml of peripheral blood in both
ewborn macaques (Fig. 5B). Mmu 29801 showed poor
eight gain and was euthanized at 4 weeks p.i.; salient
eatures at necropsy were lymphoid depletion, thymic
trophy, and severe meningioencephalitis and gastritis
Table 1). The brain pathology was suspected to be due
o the viral opportunists rhesus cytomegalovirus (rhCMV)
nd simian vacuolating virus 40 (SV40). The second new-
orn, Mmu 29800, exhibited diarrhea and weight loss
nd was euthanized at 31 weeks p.i. (Table 1). Postmor-
em examination of Mmu 29800 revealed lymphoid hy-
erplasia, thymic atrophy, and severe eosinophilic bron-
hitis. This animal was also positive for the protozoal
pportunist Cryptosporidium.
FIG. 1. Scheme for inoculation of newborn and juvenile macaques wit
ive-number code. Juvenile animals are represented by unfilled circles, and
2–3 years of age) and four newborn macaques (2–3 days of age) were in
CID 50, respectively, of a cell-free preparation of SHIVSF33 by the intraven
as transfused from this animal into healthy juvenile macaques. At 104 we
sed to inoculate newborn macaques by the intravenous route and juvenSF33A infection in newborn
hesus macaques, four additional newborn animals also
ere inoculated with a cell-free preparation of SHIVSF33
y the intravenous route (Fig. 1A). These animals exhib-
ted a relatively high virus load in the first 2 weeks p.i.;
ut virus load declined to low levels thereafter in all four
nimals (Fig. 5A). Additionally, these SHIVSF33-infected
ewborn macaques maintained normal CD41 T-cell lev-
ls and did not develop any disease signs over an
bservation period of 2 years (Fig. 5B) (M. Marthas and
. Luciw, unpublished results). In summary, in newborn
acaques SHIVSF33A was pathogenic, whereas SHIVSF33
as relatively nonpathogenic.
ntiviral antibody responses in infected macaques
To establish whether macaques infected with SHIVSF33 or
HIVSF33A produced antiviral immune responses, plasma
ntibodies were measured in an ELISA containing whole
nactivated HIV-1 and HIV-2. SHIVSF33A-infected Mmu 27985
id not demonstrate a rapid decline in CD41 T cells and
ontained readily detectable levels of antiviral antibodies,
hereas the remaining SHIVSF33A-infected animals exhibit-
ng rapid CD41 T-cell decline after infection with this virus
ontained low or undetectable levels of antiviral antibodies
Table 2). It is possible that other serological methods, such
s immunoblot or virus neutralization assay, may have de-
ected antiviral antibodies in animals that were seronega-
ive by the whole virus ELISA. For comparison, juvenile
acaques infected with the pathogenic virus, SIVmac239,
roduced antiviral antibodies with titers, measured by
LISA, in a range similar to animals infected with SHIVSF33
Table 2).
equence changes in the HIV-1 env gene during SHIV
nfection
To determine whether changes occurred in HIV-1 se-
uences in SHIVSF33 during the course of infection of
mu 25814, the juvenile macaque displaying SAIDS (Fig.
B; Table 1), the region encompassing the tat, rev, vpu,
nd env genes of SHIVSF33A was amplified by PCR,
loned, and sequenced; these sequences were submit-
ed to GenBank. Figure 6 presents amino acid changes
n six clones containing env gp120 sequences of
HIVSF33A. Twenty-seven conservative and nonconserva-
ive amino acid changes were detected in the gp120
omain of all of these clones; most of these changes
ere in the variable regions. Three to four additional
hanges were unique to each clone. Interestingly, the V3
oop of the six clones gained a novel glycosylation site
F33 and SHIVSF33A. Rhesus macaques in this study were identified by a
rn animals are represented by shaded circles. (A) Four juvenile macaques
d with SHIVSF33. Juveniles and newborns received 1000 TCID50 and 500
te. (B) At 24 and 104 weeks after inoculation of Mmu 25814, whole blood
rus designated SHIVSF33A was isolated from PBMC from Mmu 25814 and
aques by exposure of oral mucosa to cell-free virus.h SHIVS
newbo
oculate
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116 LUCIW ET AL.Asn-Xaa-Ser/Thr) because the prototype sequence Asn-
sn-Arg was converted to Asn-Tyr-Thr. Also, all clones
howed a change in the crown of the V3 loop from
ly-Pro-Gly-Lys to Gly-Pro-Gly-Arg. Other consistent
hanges in gp120 sequences were (i) the loss of a
lycosylation site near the V1 region, (ii) a loss and gain
f a glycosylation site in the V2 region in five of six
lones, and (iii) a gain of a glycosylation site in the V5
egion. Three of the six clones exhibited a loss of a
lycosylation site in the V4 region. The transmembrane
ubunit of env, gp41, showed only three amino acid
hanges (Ala at 663 to Thr, Val at 618 to Ile, Ser at 678 to
ly) (submitted to GenBank). At 72 weeks p.i., the pre-
ature stop codon at position 2 in the vpu gene reverted
o a codon for Gln (submitted to GenBank). A small
umber of amino acid changes were noted in tat, rev, nef
nd the LTR in some but not all SHIVSF33A clones exam-
ned (data not shown).
FIG. 2. Virus load and CD41 T-cell numbers in juvenile macaques ino
ollected from Mmu 25814 infected with SHIVSF33. Virus loads are also g
IVmac239nef1. (B) CD41 T-cell numbers in peripheral blood were deAmino acid sequence changes in the env gene also
ere determined for virus in Mmu 26240, which re-
ained healthy with low virus load throughout the
ourse of infection with SHIVSF33 (Fig. 1A). Analysis of five
lones, containing the gp120 domain, from virus recov-
red from this animal at 2 years after inoculation, re-
ealed three clones with no sequence changes and two
lones with one (Val at position 256 to Met) or two
hanges (Glu at position 102 to Gly, Ser at position 210 to
ro) (submitted to GenBank). These changes in the two
p120 clones from Mmu 26240 did not affect potential
lycosylation sites and did not match any changes in the
ix gp120 clones from SHIVSF33A (Fig. 6).
n vitro replication and cytopathology of SHIVSF33A
To explore potential differences in replication of the input
irus SHIVSF33 and SHIVSF33A in vitro, cultures of macaque
with SHIVSF33. (A) Cell-associated virus load was monitored in PBMC
r two juvenile macaques infected with the pathogenic molecular clone
d by flow cytometry.culated
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117SHIV AND SIMIAN AIDS IN MACAQUESBMC and the CEMx174 cells were infected with cell-free
tocks of these two viruses. SHIVSF33(vpu1) was selected
or this comparison because SHIVSF33A also encodes a full
pu translation frame. In both cell systems, SHIVSF33A ex-
ibited more rapid replication kinetics and attained higher
evels of virus in culture supernatants than SHIVSF33vpu1
Fig. 7). Additionally, observations by light microscopy re-
ealed that cytopathic effects (i.e., vacuolization and syncy-
ium formation) were detected earlier and to a greater
xtent in CEMx174 cells and PBMC cultures infected with
HIVSF33A than in cultures infected with SHIVSF33vpu1 (data
ot shown).
To more directly examine viral cytopathology, two env
p120 genes cloned from SHIVSF33A (44.9 and 52-15, Fig.
) were tested for fusogenic capacity in a cell-fusion
ssay. These two env clones displayed eight amino acid
ifferences from each other, including differences in the
2, V3, and V4 loops. First, to compare levels of env
lycoprotein expression, BHK-21 cells were transfected
ith mammalian cell expression plasmids containing the
nv gene of SHIVSF33 (pND-33) or containing the env
lones 44.9 (pND-33A1) and 52.15 (pND-33A2) (Fig. 6). At
8 h after transfection, lysates of transfected BHK-21
ells were prepared and analyzed by immunoblot for env
lycoprotein expression. All three expression vectors
Clinical and Pathologic Findings in Rhesus
Animal no. and
age at inoculation Route of inoculationa
Clinical
l
Mmu 25814
39 mo.
Intravenous
(cell-free SHIVSF33)
CD41 T-cell
weight loss
Mmu 27823
28 mo.
Transfusion
(peripheral blood
from Mmu 25814)
Rapid CD41
Mmu 27843
29 mo.
Transfusion
(peripheral blood
from Mmu 25814)
Rapid CD41
gain, lymph
Mmu 27985
32 mo.
Oral mucosa
(cell-free SHIVSF33A)
Normal CD41
Mmu 28498
28 mo.
Oral mucosa
(cell-free SHIVSF33A)
Rapid CD41
gain, diarrh
eosinophil
Mmu 29800
3 days
Intravenous
(cell-free SHIVSF33A
Rapid CD4 d
loss, high e
Mmu 29801
3 days
Intravenous
(cell-free SHIVSF33A)
Rapid CD41
dehydratio
eosinophil
a Mmu 27823 and Mmu 27843 were inoculated by transfusing blood c
acaques in this table were inoculated with a cell-free preparation ofroduced similar amounts of env glycoprotein (Fig. 8A).
mall differences in electrophoretic mobility were ob-
erved in the gp120 and gp160 forms between/among
he env glycoproteins (Fig. 8A); these differences may be
ue to differences in glycosylation patterns. For the fu-
ion assay, BHK-21 cells were transfected with each
lasmid vector and cocultured with either CEMx174 or
M-1 cells at 48 h after transfection. Formation of
ultinucleate syncytia, detected by light microscopy at
h after initiation of the coculture, was four- to eightfold
reater for the two SHIVSF33A env clones (pND-33A1 and
ND-33A2) compared with the env gene of SHIVSF33
pND-33) (Fig. 8B). Thus in vivo passage of the chimeric
iral clone resulted in altered in vitro phenotypes, which
ncluded augmented viral replication in macaque PBMC
Fig. 7A) and also enhanced fusogenicity of the env gene
Fig. 8B).
DISCUSSION
HIV pathogenesis in juvenile and newborn
acaques
This paper reports the derivation and characterization
f a pathogenic chimeric virus, SHIVSF33, which contains
he env region of the T-cell line tropic HIV-1SF33 virus on
ues Infected with SHIVSF33 and SHIVSF33A
nd premortem
ry data Postmortem findings
, lymphadenopathy, Necropsy at 128 weeks p.i., lymphoid
hyperplasia and depletion, lymphocytic
interstitial pneumonia, enteritis,
extensive bacterial colonization,
Pneumocystis carinii
ecline, weight loss Necropsy at 51 weeks p.i., lymphoid
depletion in spleen and multiple lymph
nodes, chronic active peritonitis,
overwhelming, bacterial infections and
abdominal abscesses
ecline, no weight
pathy
Necropsy at 35 weeks p.i., lymphoid
hyperplasia, severe pneumocystosis,
P. carinii
l levels Alive and healthy at 102 weeks p.i.
ecline, low weight
ermittent high
Bell’s palsy
Necropsy at 50 weeks p.i., widespread
lymphoid depletion, thymic atrophy,
gastritis, enteritis, giant cell
pneumonia, pneumocystosis,
Helicobacter, M. avium, P. carinii
diarrhea, weight
hil levels
Necropsy at 31 weeks p.i., lymphoid
hyperplasis in spleen and multiple
lymph nodes, thymic atrophy,
Cryptosporidium
ecline,
eight gain, high
Necropsy at 4 weeks p.i., lymphoid
depletion, thymic atrophy, severe
meningioencephalitis, severe gasritis
from SHIVSF33-infected Mmu 25814 at 104 weeks p.i., (Fig. 1). All other
33A obtained from PBMC of Mmu 25814 at 104 weeks p.i., (Fig. 1).Macaq
signs a
aborato
decline
T-cell d
T-cell d
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T-cel
T-cell d
ea, int
levels,
ecline,
osinop
T-cell d
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118 LUCIW ET AL.he background of the pathogenic SIVmac239 clone. This
himera utilizes the CXCR4 coreceptor for entry into cells
Chakerian et al., 1997). One of four juvenile rhesus
acaques inoculated with SHIVSF33 developed an AIDS-
ike disease commencing at 72 weeks p.i. Virus recov-
red from this animal, designated SHIVSF33A, produced
atal immunodeficiency in juvenile and newborn ma-
aques after inoculation by intravenous or mucosal
embrane routes. In contrast, the chimeric clone
HIVHXB2 (containing the env region of T-cell line tropic
IV-1 HXB2) required multiple serial passage in neme-
trina macaques to produce pathogenic virus (SHIVKU-1)
Joag et al., 1996). Also, multiple serial passage of
HIV89.6 (containing the env gene of dualtropic HIV-
89.6) in rhesus macaques was important for generating
pathogenic virus (SHIV89.6P) (Reimann et al., 1996). It is
ossible that host differences, such as immunogenetic
FIG. 3. Cellular localization of viral nucleic acid in SHIV infected
eeks after infection with SHIVSF33, shows the localization and d
ybridization signal for SHIV nucleic acid) at low magnification (200
olocalization of viral RNA by in situ hybridization in macrophages
AM-56 (red-orange AEC chromogen). (C) Lung was collected from
ransfusion from Mmu 25814 (Fig. 1B); this section shows distributio
ung tissue, viewed at higher magnification (3500), reveals cells dou
iral nucleic acid (black silver grains).actors, may have accounted for the finding that the
erivation of pathogenic SHIVSF33A did not require multi-
le passages in macaques. Accordingly, a likely scenario
s that the animal Mmu 25814 allowed sufficient levels of
eplication of the SHIVSF33 inoculum during the chronic
hase of infection to generate a viral variant(s) that pro-
uced immunodeficiency. Age is a host factor that influ-
nces disease progression in HIV-1-infected patients
Mueller and Pizzo 1997) and SIV-infected macaques
Marthas et al., 1995). Similarly, we observed that
HIVSF33A produced more rapid disease progression in
ewborn macaques than juvenile animals.
Host genetic differences also may account for the fact
hat not all animals infected with the same virus exhib-
ted the same pattern of virus load and disease progres-
ion (Bontrop et al., 1996; Sauermann et al., 1997). Con-
istent with the idea that host factors influence infection
ues. (A) A peripheral lymph node, collected from Mmu 25814 at 92
tion of viral nucleic acid (black silver grains representing in situ
At higher magnification (3500), this same lymph node shows the
ohistochemically labeled with the macrophage cytoplasmic marker
7843 at necropsy at 35 weeks after infection of this animal by blood
al nucleic acid (silver grains at 3200 magnification). (D) The same
eled with HAM-56 for macrophages (AEC chromogen) that containmacaq
istribu
X). (B)
immun
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119SHIV AND SIMIAN AIDS IN MACAQUESith chimeric virus is the observation that macaques
nfected with SHIV constructs containing the env gene of
IV-1DH12 displayed different patterns of CD41 T-cell
oss (Shibata et al., 1997). In two juvenile macaques
nfected with SHIVSF33A by the oral mucosal route in our
tudy, one animal (Mm 28498) showed a rapid CD41
-cell decline, moderate virus loads, and simian AIDS,
hereas the second animal (Mm 27985) survived for .2
ears with normal levels of CD41 T cells, low virus loads,
nd no clinical signs of immunodeficiency disease. In a
revious study, some female macaques infected with
HIVSF33A via vaginal mucosal membranes showed a
apid decline in CD41 T cells, whereas others retained
ormal levels of this cell subset (Harouse et al., 1998).
lternatively, it is possible that inoculation across muco-
al membranes selects for viral variants that differ in
athogenic potential (Lu et al., 1996; Trivedi et al., 1996).
FIG. 4. Virus load and CD41 T-cell numbers in juvenile macaques i
lood transfusion (5 ml) from Mmu 25814 at 104 weeks p.i. Mmu 2798
HIVSF33A. For all of these animals, cell-associated virus load was monito
low cytometry.A major feature of infection of macaques with patho-
enic SHIV is rapid and severe depletion of CD41 T cells;
his depletion occurs in most animals infected with
hese chimeric viruses (Joag et al., 1996; Reimann et al.,
996; Steger et al., 1998). In contrast, infection with SIV-
ac239 or other strains of SIV generally produces little
r no effect on total number of CD41 T cells throughout
he course of infection, except in terminal stages of
imian AIDS when this subset of T cells declines
Reimann et al., 1994). The basis for the rapid loss of
D41 T cells in pathogenic SHIV infection is not known.
potential explanation is that pathogenic SHIV isolates
re more cytopathic for CD41 T cells in vivo than either
IVmac239 or nonpathogenic SHIV isolates. Alterna-
ively, pathogenic SHIV isolates might more profoundly
ffect precursors of CD41 T cells, thereby preventing
eplenishment of cells in this subset (Ho et al., 1995; Wei
d with pathogenic SHIV. (A) Mmu 27823 and Mmu 27843 received a
Mmu 28498 were inoculated by exposure of oral mucosa to cell-free
BMC. (B) CD41 T-cell numbers in peripheral blood were determined bynoculate
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120 LUCIW ET AL.t al., 1995; Rosenzweig et al., 1998). The enhanced
bility of SHIVSF33A to infect and replicate in cultures of
hesus lymphoid cells and to produce cytopathic effects
n such cultures may provide an explanation for the
athogenic nature of this virus compared with the input
irus SHIVSF33. Although direct killing of CD41 T cells in
ivo by pathogenic SHIV may account for the rapid and
ustained depletion of this lymphocyte subset, it is also
ossible that an indirect mechanism(s), such as disrup-
ion of lymphocyte homeostatic mechanisms in the host,
ay contribute to CD41 T-cell depletion (Pantaleo and
auci, 1996).
iral sequence changes during in vivo passage
f SHIV
A key issue to understanding the determinant(s) of
HIV adaptation to viral persistence, CD41 T-cell deple-
FIG. 5. Virus load and CD41 T-cell numbers in SHIVSF33 and
HIVSF33A-infected newborn macaques. (A) Cell-associated virus load
as monitored in PBMC collected from two newborns inoculated with
HIVSF33A and four newborn macaques inoculated with SHIVSF33
mean virus load for four animals). (B) CD41 T-cell numbers in periph-
ral blood were determined by flow cytometry for two newborns
noculated with SHIVSF33A and four newborns infected with SHIVSF33
mean CD41 T-cell counts for four animals).ion, and disease is the sequence change(s) in the chi-
eric virus during in vivo passage. Such a change(s)
ight confer increased infectivity of the SHIV for ma-
aque target cells (e.g., CD41 T cells, monocytes/mac-
ophages, and/or dendritic cells) or enable the virus to
scape the host immune response. Both of these mech-
nisms for SHIV adaptation to pathogenesis are not
utually exclusive.
Comparisons of SHIVSF33 and SHIVSF33A revealed
mino acid changes in HIV-1SF33 vpu, tat, rev, and both
ubunits of env. Other investigators also have reported a
mall number of substitutions in vpu, tat, and rev for the
athogenic isolates SHIVKU-1 and SHIV89.6P (Karlsson et
l., 1997; Stephens et al., 1997). Restoration of the vpu
ranslation frame in SHIVSF33A was probably important for
iral persistence. However, this reversion in vpu is not
he sole determinant for pathogenesis; a previous study
f SHIV-4 (constructed from HIV-1HXB2) revealed that vpu
layed a role in viral persistence but was not sufficient to
ause simian AIDS (Li et al., 1995). The changes in tat
nd rev generally involved synonymous substitutions;
TABLE 2
Levels of Antiviral Antibodies in Juvenile and Newborn Macaques
Infected with SHIVSF33 or SHIVSF33A
Animal Inoculum
Weeks
postinfectiona Titerb
mu 25814 SHIVSF33 52 1/102,400
(juvenile) 128 (necropsy) 1/12,800
mu 28156
(newborn)
SHIVSF33 52 1/800
mu 28158
(newborn)
SHIVSF33 52 1/12,800
mu 28176
(newborn)
SHIVSF33 52 1/3,200
mu 28177
(newborn)
SHIVSF33 52 1/3,200
mu 27823 Transfusion from 24 1/200
(juvenile) Mmu 25814 51 (necropsy) 1/200
mu 27843 Transfusion from 24 ,1/100
(juvenile) Mmu 25814 35 (necropsy) ,1/100
mu 29800
(newborn)
SHIVSF33A 31 (necropsy) 1/800
mu 29801
(newborn)
SHIVSF33A 2 ,1/100
mu 27985 SHIVSF33A 24 1/3,200
(juvenile) 52 1/3,200
mu 28498 SHIVSF33A 24 ,1/100
(juvenile) 50 (necropsy) ,1/100
mu 26084 SIVmac239 24 1/3,200
(juvenile) 51 (necropsy) 1/6,400
mu 27098 SIVmac239 24 1/1,024,000
(juvenile) 83 (necropsy) 1/819,200
a Weeks after inoculation with cell-free virus or after blood transfu-
ion.
b Levels of antiviral antibodies in plasma samples were measured in
whole virus ELISA containing a mixture of HIV-1 and HIV-2 antigens
Genetics Systems, Seattle, WA). Titers shown as ,1/100 are below the
etection level of the ELISA.
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121SHIV AND SIMIAN AIDS IN MACAQUESdditionally, these changes were different for the three
athogenic SHIV isolates.
For SHIVSF33A, most of the amino acid sequence sub-
titutions were in the env gene, and the majority of these
ere in the variable regions of the gp120 subunit.
FIG. 6. Sequence changes in the SHIVSF33A envelope glycoprotein. S
Fig. 1B). The top line shows the sequence of the gp120 env subunit of
equences for six clones representing the gp120 domain of SHIVSF33A.
re underlined. DNA sequences are deposited in GenBank.HIVKU-1 and SHIV89.6P both exhibited 10 changes in
p120 when compared with each of their predecessor
lones SHIV-4 and SHIV89.6, respectively; however,
hese changes were different for both of these viruses
nd did not match the 24 amino acid changes acquired
A is the virus obtained from Mmu 25814 at 104 weeks after inoculation
F33 in the one letter amino acid code. This figure shows differences in
regions V1 to V5 are overlined. Potential glycosylation sites (N-X-S/T)HIVSF33
HIV-1S
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122 LUCIW ET AL.y SHIVSF33A. A recent structural model of the gp120
ubunit identified several amino acid residues, highly
onserved among numerous HIV-1 subtype-B isolates,
hich are located in the site for attachment to the CD4
FIG. 7. In vitro replication of chimeric viruses. Comparisons were
ade in the replication of SHIVSF33vpu1 and SHIVSF33A. Cultures of
EMx174 cells (A) and stimulated PBMC from two uninfected ma-
aques (Mmu 23587 and Mmu 23020; B and C, respectively) were
nfected with 1000 TCID50 of each virus per 10
6 cells. Uninfected
ultures, designated “mock,” were included for each cell type. Samples
f culture media were collected and assayed for SIV p27gag by ELISA
t 3- to 4-day intervals. h, Mock infection; E, SHIV-33vpu1; , SHIV-33A.ntigen and in the site for interaction with the coreceptor
n cell membranes (Kwong et al., 1998; Rizzuto et al.,
998). None of the substitutions in the gp120 subunit of
hese three pathogenic SHIV isolates involved substitu-
ions in these residues. The structural model also pre-
icts that the V1 and V2 loops play a role in attachment
o the coreceptor. Additionally, genetic studies of viral
utants, analyzed in tissue culture systems, also indi-
ate that the V3 loop influences coreceptor usage (Coc-
hi et al., 1996; Wu et al., 1996). Thus the changes in the
1, V2, and V3 loops, which occurred during in vivo
assage of each chimeric virus, could influence core-
eptor usage in a qualitative and/or quantitative fashion
nd could consequently affect cell tropism (Doms and
oore 1997; Platt et al., 1998).
Although all three pathogenic SHIV isolates
SHIVSF33A, SHIVKU-1, and SHIV89.6P) contained substitu-
ions in the V3 epitope, only SHIVSF33A acquired a (po-
ential) glycosylation site in this loop. Previous investiga-
ors demonstrated that presence of a glycosylation site
n the HIV-1 V3 loop enhanced resistance of virus to
eutralizing antibody (Back et al., 1994; Schonning et al.,
996) and altered the efficiency of coreceptor usage
Nakayama et al., 1998). Further studies are required to
etermine whether the new (potential) glycosylation site
n V3 of SHIVSF33A affects virus neutralization by antibody
nd/or a env-mediated function in viral replication. None-
heless other changes in V3, as well as other regions of
nv, could be a consequence of immune selection by the
ost (McMichael et al., 1997).
All three pathogenic chimeras (SHIVSF33A, SHIVKU-1,
nd SHIV89.6P) acquired three to four amino acid
hanges in the gp41 subunit that were unique to each
irus. In addition, SHIV89.6 exhibited a deletion at the
arboxyl-terminus of gp41 that removed 42 amino acid
esidues (Karlsson et al., 1997). This deletion joined the
ranslation frame for HIV-1 gp41 with the portion of the
arboxyl-terminus of SIVmac239 gp41 that overlaps the
ef gene (57 amino acid residues) to produce a hybrid
ransmembrane glycoprotein. SHIVSF33A and SHIVKU-1
id not show such a drastic alteration in the env trans-
embrane glycoprotein (Fig. 6; Stephens et al., 1997);
his finding indicates that the deletion event producing
he hybrid gp41 subunit is unique to SHIV89.6P and may
ot be important for viral adaptation and pathogenesis
Karlsson et al., 1998).
nvestigation of env determinants of SHIV
athogenesis
Pathogenic SHIV isolates are being used to analyze
he roles of various HIV-1 env genes in the virus/host
elationship and as challenge viruses in vaccine studies
n nonhuman primate models for lentivirus infection and
imian AIDS (reviewed in Overbaugh et al., 1996; Warren
nd Levinson 1997). SHIVSF33A, similar to other patho-
enic chimeric viruses, causes a rapid and sustained
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123SHIV AND SIMIAN AIDS IN MACAQUESepletion in CD41 T cells, and this depletion occurs in
nimals infected with cell-free virus by the intravenous
oute as well as by vaginal (Harouse et al., 1998) or oral
ucosa (Joag et al., 1997; Lu et al., 1998). Thus this pair
f chimeric viruses, SHIVSF33 and SHIVSF33A, can be used
o examine the role of the HIV-1 env gene in viral patho-
enesis and transmission through mucosal membranes.
omparisons of sequences of three pathogenic chime-
as (i.e., SHIVSF33A, SHIV89.6P, and SHIVKU-1) have not
evealed a simple picture of the amino acid changes in
he env glycoprotein that correlate with conversion of
onpathogenic to pathogenic virus. Further studies with
oint mutants and intragenic recombinants in the gp120
ubunit of env will be necessary to determine which
hange(s) is (are) important for adaptation and disease
n the macaque host.
A measurable phenotype(s) based on an in vitro assay
i.e., in tissue culture) will be important for elucidating mo-
ecular mechanisms of SHIV immunodeficiency. Accord-
ngly, further studies are required to determine whether the
ugmented replication and cytopathicity of SHIVSF33A is
mportant for the rapid CD41 T-cell decline in vivo. The
athogenic SHIV89.6P contains an env gene that also dis-
lays higher fusion capacity and increased coreceptor
inding capacity than the nonpathogenic SHIV89.6 (Karls-
FIG. 8. Cell fusion assay for SHIVSF33 and SHIVSF33A env. The mamma
ectors pND-33A1 and pND-33A2 contain the env clones 44.9 and 52.15,
nalysis or in 24-well microtiter plates for fusion assay, were transfected
A) Levels of env glycoproteins (gp160 precursor and gp120 surface doma
lectrophoresis on 8% polyacrylamide gels followed by immunoblot analy
EMx174 or PM-1 cells were added to BHK-21 cell cultures (in 24-well micr
or each plasmid vector). Multinucleate syncytia, containing 4 or more nuc
f the coculture. No syncytia were detected in transfections with the con
epresent the average obtained from counting syncytia in a total of six fieldon et al., 1998). Both SHIVSF33 and SHIVSF33A utilize the
XCR4 coreceptor (Harouse et al., 1998); it is possible that
hese two viruses may differ in the usage of other (novel)
oreceptors in macaques (Farzan et al., 1997; Hoffman et
l., 1998). Interestingly, pathogenic SHIVKU-1 differed from
ts nonpathogenic predecessor by exhibiting higher levels
f replication in macaque macrophages (Stephens et al.,
997). Potential differences in cell tropism between
HIVSF33 and SHIVSF33A remain to be determined. It is pos-
ible that sequence changes in env also may enable virus
o escape host immune responses (McMichael and Philips
997). Evolution of HIV-1 in humans and SIV in susceptible
acaques involves changes in viral phenotypes (corecep-
or usage, cytopathicity) and antigenic properties, and
hese changes appear to correlate with disease progres-
ion (Connor et al., 1994; Wolinsky et al., 1996; Rudensey et
l., 1998). The results in this study, on the nonpathogenic
nd pathogenic pair SHIVSF33 and SHIVSF33A, respectively,
aken together with reports on such pairs of other SHIV
solates (Joag et al., 1996; Reimann et al., 1996; Karlsson et
l., 1998), set the stage for analyzing functions of the HIV-1
nv glycoprotein and its domains in viral pathogenesis and
or studying antiviral immune responses in nonhuman pri-
ate models for AIDS.
ll expression vector pND-33 contains the env gene of SHIVSF33, and the
tively (Fig. 6). Cultures of BHK-21 cells, in 35-mm plates for immunoblot
ch of these three expression plasmids or pND-14 (empty vector control).
HK-21 cell lysates, prepared at 48 h after transfection, were assessed by
anti-HIV-1 env gp120 polyclonal antibody. (B) At 48 h after transfection,
ates) previously transfected with each plasmid vector (quadruplicate wells
e detected by light microscopy (3100 magnification) at 9 h after the start
tor pND-14 (data not shown). The values given for each plasmid vector
ell (four wells per plasmid vector). Error bars indicate standard deviation.lian ce
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124 LUCIW ET AL.MATERIALS AND METHODS
ells and viruses
Peripheral blood mononuclear cells (PBMC) were ob-
ained from healthy rhesus macaques free of simian type-D
etroviruses (SRV), SIV, and simian T-lymphotropic virus
STLV). These cells, purified from whole blood by Ficoll–
ypaque centrifugation, were stimulated with staphylcoc-
al enterotoxin A (SEA) and maintained in RPMI 1640 me-
ium supplemented with 10% heat-inactivated (56°C for 30
in) fetal calf serum (FCS) and 10% interleukin-2 (IL-2)
Chiron Corp., Emeryville, CA) and antibiotics (100 units/ml
enicillin and 100 mg/ml streptomycin). CEMx174 cells, a
uman hybrid T–B-cell line (provided by Dr. J. Hoxie, Uni-
ersity of Pennsylvania, Philadelphia, PA), were maintained
n RPMI 1640 medium supplemented with 5% calf serum
lus 5% fetal calf serum and antibiotics. PM-1 cells (ob-
ained from Dr. R. Gallo, University of Maryland, Baltimore,
D) are a human T-cell line permissive for primary as well
s T-cell line adapted strains of HIV-1 (Lusso et al., 1995).
M221 cells (provided by Dr. R. Desrosiers, New England
egional Primate Research Center, Southboro, MA) are an
L-2-dependent rhesus macaque T-cell line permissive for
IV and SHIV (Alexander et al., 1997). BHK-21 (baby ham-
ter kidney cells) were obtained from the American Type
ulture Collection (Rockville, MD).
The stock of cell-free SHIVSF33 was previously described
Luciw et al., 1995). SHIVSF33vpu1 was produced by chang-
ng the premature stop codon at position 2 in vpu to a
lutamine codon by site-directed mutagenesis (C. Cheng
ayer). Both SHIVSF33vpu1 and SHIVSF33A were propa-
ated in a large culture of CEMx174 cells. Culture superna-
ants were collected at 5–6 days p.i. (when ;25% of cells
isplayed cytopathic effects), passed through a 0.22-mm
ilter, and frozen in 1-ml aliquots. The 50% tissue culture
nfectious dose (TCID50) of these viral stocks in CEMx174
ells was determined by end-point dilution in microtiter
lates as described previously (Marthas et al., 1993).
hesus macaques and viral inoculations
All animals were colony-bred juvenile rhesus ma-
aques (Macaca mulatta) free of SRV, SIV, and STLV;
hese animals are housed at the California Regional
rimate Research Center (CRPRC) at Davis, CA, in ac-
ordance with American Association for Accreditation of
aboratory Animal Care Standards. Neonatal macaques,
orn to dams seronegative for SRV, SIV, and STLV, were
emoved from their mothers and reared in a primate
ursery. Before inoculation, 20 ml of blood from juvenile
acaques and 1 ml from newborn macaques (2–3 days
f age) was collected by venipuncture for complete blood
ount (CBC) including platelet count, CD4/CD8 T lympho-
yte phenotyping by flow cytometry, and for preinfection
lasma and PBMC samples. From juvenile macaques,
eripheral lymph nodes were obtained by excisional
iopsy, and portions of lymph nodes were fixed in form-ldehyde and OCT. The scheme for inoculating juvenile
nd neonatal macaques is shown in Fig. 1. Juvenile
acaques received a 5-ml blood transfusion from Mmu
5814 at 24 and 104 weeks p.i. For transmission across
ucosal membranes, oral mucosa of juvenile macaques
ere exposed to 1 ml of cell-free SHIVSF33A containing
6,000 TCID50. Neonatal macaques were inoculated with
00 TCID50 of 0.5 ml of cell-free SHIVSF33A by the intra-
enous route. Animals were observed daily and weighed
egularly by the CRPRC veterinary staff. Complete phys-
cal examinations were performed to monitor for weight
oss, lymphadenopathy, and/or splenomegaly, opportu-
istic infections as well as any other clinical signs of
isease. Animals meeting three of the following criteria
ere euthanized: (i) weight loss .10% in 2 weeks or 30%
n 3 months, (ii) chronic diarrhea unresponsive to treat-
ent, (iii) infections unresponsive to antibiotics, (iv) in-
bility to maintain body heat or fluids without supplemen-
ation, (v) persistent, marked hematological abnormali-
ies including lymphopenia, anemia, thrombocytopenia,
r neutropenia, and (vi) persistent, marked splenomegaly
r hepatomegaly. A complete necropsy was performed
n each euthanized animal; this included gross and
icroscopic examination of tissues.
easures of viral load
Levels of viral antigen in plasma were measured with an
LISA kit for SIV p27gag antigen (Coulter Immunology, Hi-
leah, FL). For measuring plasma viremia, serial 10-fold
lasma dilutions were made in tissue culture medium and
ispensed into 24-well microtiter plates containing 2.5 3
05 CEMx174 cells (Marthas et al., 1993). Cultures in these
lates are passaged every 3–4 days over a 4-week period.
our replicates were made for each dilution. Growth of virus
s scored by microscopic observation of cytopathology and
y measuring viral antigen in tissue culture supernatant
ith the SIV p27gag ELISA kit. For measuring cell-associated
iral loads, 106 PBMC or lymph node cells (and serial
0-fold dilutions of these cells) from each infected macaque
ere cocultured with 2.5 3 105 CEMx174 cells per well with
our wells per dilution (Marthas et al., 1993). These cocul-
ures were monitored by light microscopy for cytopathology,
nd samples of media were assayed for SIV p27gag antigen
y the ELISA kit to monitor virus production. Titers were
alculated by the method of Reed and Meunch to deter-
ine the number of infected PBMC per 106 total PBMC. To
easure virus load in lymph nodes, peripheral lymph
odes were obtained by transcutaneous biopsy and asep-
ically teased into single-cell suspensions; cell numbers
ere determined by counting in a hemocytometer.
ematological evaluation and CD4/CD8 T-lymphocyte
mmunophenotyping
Complete blood counts (CBC) were performed by a
tandard automated method (Biochem Immunosystems,
llentown, PA) on EDTA anticoagulated blood. CD4 and
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125SHIV AND SIMIAN AIDS IN MACAQUESD8 T lymphocyte immunophenotyping was performed
y flow cytometry using a two-color whole-blood lysis
echnique (Q-Prep, Coulter, Hialeah, FL) (Reimann et al.,
994). Fifty microliters of whole blood was incubated in
he dark at 25°C with anti-CD4 (Leu3a, Becton Dickin-
on, Mountain View, CA) and anti-CD8 (Leu2a, Becton
ickinson, Mountain View, CA)-specific monoclonal an-
ibodies according to manufacturer’s instructions and
ere analyzed by flow cytometry using a FACSCAN (Bec-
on Dickinson, Mountainview, CA).
etection of virus in tissues
In situ hybridization/immunohistochemistry was per-
ormed as previously described (Heise et al., 1993; Man-
ell et al., 1995). A 9-kb SIVmac239 genomic DNA frag-
ent containing the entire gag, pol, and env regions was
adioactively labeled with [35S]CTP by random priming in
DNA polymerase reaction to synthesize a SIV DNA
robe with a specific activity of $ 1 [mult] 108 cpm/mg. To
etect both SIV DNA and RNA, slides with coverslips
ere heated at 95°C for 7 min, cooled on ice for 3 min,
hen incubated overnight at 37°C in humidification cham-
ers. In situ hybridization experiments were repeated at
east three times to verify consistency of results. Control
amples included 4% paraformaldehyde fixed SIV-in-
ected and uninfected cultured CEMx174 cells, hybridiza-
ion of lymph node and gastrointestinal tissue from SIV-
nfected and uninfected monkeys, hybridization with
robe containing only the pSP64 vector, and RNase treat-
ent of tissue before hybridization. Monocyte/macro-
hages and T lymphocytes were localized, respectively,
sing a monoclonal antibody specific for macrophages
HAM-56, DAKO Corporation, Carpentieria, CA) and a
olyclonal antibody specific for CD31 T lymphocytes
CD3, DAKO). These antibodies have been validated for
se on uninfected and infected rhesus macaque tissues
Mandell et al., 1995).
olymerase chain reaction (PCR) and sequencing
f viral DNA
For PCR amplification of viral DNA, a forward primer to
onserved SIVmac239 sequence (6631nt) and a reverse
rimer 39 of the HIV-1-SF33 env SU/TM cleavage site
2157nt) were used. Nucleotide (nt) positions are from the
equence of SIVmac239 clone (GenBank Accession No.
33262) and HIVSF33 (GenBank Accession No.
38427), respectively. Oligonucleotide primers were de-
igned with Amplify v1.0 (Bill Engels, University of Wis-
onsin, Madison, WI). The forward primer is SHIV115.24
r SHIV121.26 (59CGGATGCATCCACTCCAGAATCGG or
9GGCGGATGCATCCACTCCAGAATCGG) and the re-
erse primer is SHIV116.24 or SHIV122.25 (59TGTTGC-
CCTCAATAGCTCTCAGC or 59GTGTTGCGCCTCAAT-
GCTCTCAGC). The sequence of primers SHIV121 and
HIV122 is the sequence of primers SHIV115 and
HIV116 with G and GG added, respectively, to the 59nd. This 59 G addition increases the terminal trans-
erase activity of Taq DNA polymerase to add A to the 39
nd, thereby increasing cloning efficiency with DNA syn-
hesized with thermophilic polymerases. Template for
mplification was prepared from CEMx174 cells infected
ith SHIV33A virus stock (26,303 TCID50/ml) and lysed at
ay 7 p.i. PCR was done with 0.5–2 ml of lysate in a final
olume of 50 ml of the following reaction mix: 10 mM
ris–HCl, pH 8.3; 50 mM KCl; 1.5 mM MgCl2; 200 mM
ach dATP, dCTP, dGTP, and dTTP; 20–40 pmol of each
rimer; and 1–1.5 units AmpliTaq DNA polymerase (Per-
in-Elmir Cetus), overlayed with 40 ml of mineral oil. This
eaction mix was transferred to a DNA thermal cycler
Perkin–Elmer Cetus), one cycle at 94°C for 4 min, fol-
owed by 30 cycles at 94°C for 1 min, 60°C for 1 min, and
2°C for 2 or 3 min followed by 20–90 min at 72°C
ncubation. The 2170-nt PCR product for clones 44.1 and
4.9 was Qiaex (Qiagen, Valencia, CA) purified from
garose gel electrophoresis of the PCR reaction and
igated to pCR2.1 using the TA cloning kit (Invitrogen,
arlsbad, CA). For clones 52.12, 52.13, and 52.15, 3 ml of
he PCR reaction was directly ligated to pCR2.1 using the
A cloning kit (Invitrogen, Carlsbad, CA); and for clone
3.10, the PCR reaction was processed with the QIAquick
CR purification kit (Qiagen, Valencia, CA) and ligated to
he pCR2.1 using the TA cloning kit. Plasmid clones were
creened for insert size and sequenced. Amino acid
lignment was determined using GeneWorks (Oxford
olecular, Campbell, CA). The DNA sequences of these
lones are deposited in GenBank and will be available
imultaneous with publication of this report.
lasmid vectors for env gene expression and cell
usion assay
The gp160 env gene of SHIVSF33 and the two clones
rom SHIVSF33A were inserted into the mammalian cell
xpression vector pND-14, which contains the cytomeg-
lovirus immediate early promoter and intron-A, the con-
titutive transport element of the simian type-D retrovi-
us-1, and the poly(A) signal from bovine growth hormone
G. Rhodes and P. Luciw, unpublished results). This vec-
or also contains the signal leader sequence of tissue
lasminogen activator (TPA) followed by an oligonucleo-
ide polylinker with several unique restriction enzyme
ites for cloning (Chapman et al., 1991). PCR amplified
nv gene DNA fragments were cloned into the polylinker
o that the TPA signal leader substituted for the env gene
eader. pND-33 contains the HIV-1SF33 env gp160 gene.
he KpnI to MunI DNA fragment, containing most of the
p120 sequences, was prepared from SHIVSF33A env
lone 44.9 and clone 52.15 (Fig. 6) and used to replace
he counterpart region in pND-33 to produce pND-33A1
nd pND-33A2, respectively. For immunoblot analysis, a
5-mm plate of BHK-21 cells (3 3 105) was transfected
ith 4 mg of each plasmid expression vector in a 1–2 M
omplex of plasmid DNA (4 mg per plate) and cationic
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126 LUCIW ET AL.ipids (1:1 ratio of DOTAP: DOPE; Avanti Polar Lipids,
irmingham, AL). At 48 h after transfection, the culture
edium was removed, the cell surface was washed with
hosphate-buffered saline, and 0.2 ml of gel disruption
uffer (containing 0.4% SDS) was added. Goat polyclonal
ntibody to HIV-1-SF2 env gp120 was obtained from Dr.
. Barnett (Chiron Corporation, Emeryville, CA). Details of
crylamide gel electrophoresis and immunoblotting have
een previously described (Sawai et al., 1994). For the
usion assay, BHK-21 cells were grown in a 24-well
icrotiter plate, at 6 3 104 cells per well. Each well was
ransfected as described above but with 1 mg of plasmid
NA per well. Quadripulicate wells were transfected
ith each plasmid vector. At 48 h after transfection, the
ulture medium (1 ml) was replaced with fresh medium
ontaining 5 3 105 CEMx174 or PM-1 cells. After nine
dditional hours of incubation, individual wells were ob-
erved under a light microscope ([mult]100), and multinu-
leate syncytia were counted by identifying large cells
ontaining four or more nuclei per cell. Syncytia in a total
f six fields per well were counted (four wells per vector),
nd the average number of syncytia was calculated for
ach plasmid vector.
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